Beaumont Health announced Friday, May 29, it has canceled a planned merger with Ohio-based Summa Health, but didn’t explain why.
Under the plan, Summa would have become a subsidiary of Beaumont. The combined organizations would have had US$6.1 billion in total revenue, 45,000 employees, and 12 hospitals.
The organizations had planned to partner for over the past two years and signed a letter of intent in July 2019. They cleared all state and federal regulations, according to Becker’s Hospital Review.
“The organizations are now finalizing details and next steps to end the planned partnership,” the groups said in a joint statement.
“Throughout this process, each of the organizations has continued to operate independently, and each will continue to focus on providing exceptional health care services for their respective markets.
“Both Beaumont Health and Summa Health value the support that each organization has received from their employees, physicians and communities throughout this process and will continue to work to meet their needs moving forward.”
Beaumont is the largest hospital system in Michigan, and Summa is one of the largest integrated health systems in Ohio.
Full Content: Beaumont
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Nominates Olivia Trusty for FCC Commissioner Role Ahead of Inauguration
Jan 16, 2025 by
CPI
Lawyers Claim eXp’s Settlement Tactics Hurt Antitrust Case Potential
Jan 16, 2025 by
CPI
Amex GBT Pushes Back Against DOJ Lawsuit Over CWT Acquisition
Jan 16, 2025 by
CPI
Belgium Opens Antitrust Probe into AB InBev’s Market Practices
Jan 16, 2025 by
CPI
Tech Groups Sue CFPB Over New Rule on Digital Wallet Oversight
Jan 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand